EMA Approval Submission for Teclistamab Multipl...

By HEOR Staff Writer

March 12, 2026

Johnson & Johnson has submitted a Type II variation application to the
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Advers...
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates
South Africa’s Push for Local Lenacapavir Production to Enhance HIV Pre...
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Manage...
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
EMA’s mCombriax Vaccine Recommendation
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...